

The Weaponization of Mosquitos: WHO and Gates Inc Announce Plans to Flood Africa with Ultra Dangerous Malaria "Vaccines"

Pharma windfall could soon be worth \$1 billion in annual revenues.

By Jordan Schachtel

Global Research, March 02, 2024

The Dossier 6 July 2023

Region: <u>sub-Saharan Africa</u> Theme: Science and Medicine

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), click here.

Click the share button above to email/forward this article to your friends and colleagues. Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

The World Health Organization and its partner organization, the Bill Gates-controlled GAVI, announced Wednesday that they will be flooding Africa with 18 million doses of malaria vaccines.

During a Wednesday <u>press conference</u>, WHO director Tedros Adhanom declared that 12 African countries will be receiving 18 million doses of malaria vaccine in the coming months, declaring that climate change is largely responsible for the continuing disease burden in the continent.



While it seems like great news at the surface, considering Africa's continuing malaria epidemic, we've again encountered a situation in which the "cure" appears to be more threatening than the disease itself.

Malaria indeed plagues the African continent. It is reported to be the culprit for the annual deaths of about half a million children in sub Saharan Africa.

And before the mid 20th century, there were few medical means to defeat parasite infestations, other than to improve sanitation and living standards. Today, there are several medications that prevent and treat malaria, but do not provide sterilizing immunity to the disease.


The only malaria "vaccine" that has been rolled out thus far is an injection called Mosquirix (RTS,S/AS01), which is produced by Big Pharma giant GSK.

Mosquirix not only does not provide sterilizing immunity, it requires 4 separate shots, and its supposed preventive effects only lasts a handful of months.

Additionally, the drug is not only seemingly worthless, but uniquely dangerous.

The largest Mosquirix trials <u>produced shockingly poor results</u>, <u>with the vaccine cohort having much worse outcomes than the placebo group</u>. (McGill University Study)

The vaccine group displayed ten times higher risk of meningitis and cerebral malaria, and a doubling in the risk of death compared to the placebo group. Even if the shots "work," they do not achieve any temporary or long term sterilizing immunity or significant efficacious benefit, so in no way would it reduce the actual disease burden.



The Malaria Vaccine's Success Story Hides Legitimate Concerns

The first vaccine against malaria has just been recommended by the WHO but questions about its testing in Africa and its safety remain



Nonetheless, the notoriously corrupt and captured World Health Organization has given its stamp of approval for the dangerous vaccine, recommending it for at risk youth. They even baselessly claim on the WHO website that for every 200 malaria shots deployed, one child's life will be saved by the "vaccine."

Last year, UNICEF <u>awarded</u> GSK (which, again, is currently the lone supplier of malaria shots) with a \$170 million contract for 18 million doses of its malaria injections (\$9.44 per dose).

Now, Gates Inc and its middleman partners have <u>released a white paper</u> detailing their roadmap for the deployment of these shots. They are <u>seeking</u> to establish a system in which 80-100 million shots are injected into the arms of sub Saharan African children on an annual basis by 2030. This would create a malaria vaccine industry in Africa that is poised to rake in close to \$1 billion annually.

White paper
April 2023 | gavi.org



Malaria vaccine market shaping roadmap

Gavi harnesses the specialist knowledge of partners and other experts to produce vaccine-specific strategic demand scenarios (SDS) to improve understanding of vaccine markets. These are primarily aimed at facilitating important medium- and longer-term decisions, including those made by key stakeholders such as manufacturers and implementing countries. They can inform supply and procurement strategies, as well as highlight challenges in specific markets. Demand for malaria vaccines is predicted to be around 80-100 million doses per year by 2030, based on the 2021 Gavi SDS forecasts.

There is no evidence that these shots work to prevent malaria, but that hasn't stopped Big Pharma and global "Public Health" institutions from executing its designs upon the African continent.

The news out of Africa is remarkably timed with a continuing series of malaria <u>scare</u> stories coming out of the United States. Not to worry though, the corporate media will be sure to let you know that the Pfizer-backed BioNTech is <u>working</u> on its own malaria vaccine!

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

The original source of this article is <u>The Dossier</u> Copyright © <u>Jordan Schachtel</u>, <u>The Dossier</u>, 2024

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Jordan Schachtel

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca